Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims: To assess the pharmacokinetics ( PK ) and glucodynamics ( GD ) of LY2605541 in patients with type 2 diabetes mellitus. Methods: This parallel‐group, open‐label, dose‐escalation study examined the PK and GD of basal insulin LY2605541 after single and multiple‐dose administration. Fixed doses of LY2605541 (0.33–1.00 U/kg) were given once‐daily ( QD ) for 14 days to insulin‐treated patients with type 2 diabetes. A 24‐h euglycaemic glucose clamp was conducted on days 1 and 14. Results: PK steady state was achieved within 7–10 days and the peak‐to‐trough fluctuation was <2, translating to a nearly ‘peakless’ glucose infusion rate at steady state and with a duration of action of at least 24 h. Across dose levels t 1/2 ranged from 44.7 to 75.5 h (˜2–3 days). As steady state was achieved, there were dose‐dependent reductions in the prandial insulin dose and in fasting blood glucose, which decreased to 60–100 mg/dl across dose levels. Within‐patient variability was <14 and <26% for the area under the concentration versus time curve ( AUC ) of the 8‐point blood glucose profile and fasting blood glucose, respectively. The nocturnal glucose control between 03:00 and 09:00 hours was relatively unchanged. Mild hypoglycaemia was the most common adverse event. Conclusions: In this Phase I study of fixed LY2605541 doses without titration, LY2605541 was well‐tolerated and demonstrated a flat PK and GD profile accompanied by glucose normalization, prandial insulin dose reduction and no severe hypoglycaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Hirsch, I. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040832 · Cited by 667
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Self-citationKlein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251 · cited 1×
“While all clamps were stopped after 24 h in this study (and therefore duration of action could not be fully assessed), the mean GD profiles on day 14 were very flat and showed considerably less peak-to-trough fluctuation than observed with insulin glargine or insulin detemir [6,7,18].”
BackgroundSelf-citationInsulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Bartley, P. C., Bogoev, M., Larsen, J., & Philotheou, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02407.x · Cited by 159
Danne, T., Lüpke, K., Walte, K., von Schuetz, W., & Gall, M.-A. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3087 · Cited by 153 · cited 1×
“5 h) [15], insulin detemir (6–7 h) [16,17] and insulin degludec (25.”
BackgroundRosenstock, J., Bergenstal, R. M., Blevins, T. C., Morrow, L. A., Prince, M. J., Qu, Y., Sinha, V. P., Howey, D. C., & Jacober, S. J. (2013) · Diabetes Care · doi:10.2337/dc12-0067 · Cited by 96 · cited 1×
“A similar phenomenon was observed in a clinical study in patients with type 1 diabetes who also had to reduce their average short-acting insulin dose [20].”
Self-citation
Cited by
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407
“In contrast, longer terminal half-lives of 25 or 45–76 h, as observed for insulin degludec and LY2605541, respectively, may pose an issue for dose adjustment (20,21).”
BackgroundSelf-citationInsulin Stacking Versus Therapeutic Accumulation: Understanding the Differences
Heise, T., & Meneghini, L. F. (2014) · Endocrine Practice · doi:10.4158/ep13090.ra · Cited by 87
Self-citationPillai, S., Duvvuru, S., Bhatnagar, P., Foster, W., Farmen, M., Shankar, S., Harris, C., Bastyr, E., Hoogwerf, B., & Haupt, A. (2018) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.45 · Cited by 19
Metadata
- Authors
- Sinha, V. P., Howey, D. C., Choi, S. L., Mace, K. F., & Heise, T.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-10-31
- Volume
- 16
- Issue
- 4
- Pages
- 344-350
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1721477966
- Cited by
- 61
- References
- 10
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/dom.12222
- The paper
- Sinha, V. P., Howey, D. C., Choi, S. L., Mace, K. F., & Heise, T. (2014). Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12222
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.